参考文献: Harrison, Stephen A., et al. "Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study." Journal of Hepatology (2024). 医脉通是专业的...
1,Nauck and DAlessio; Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type2 diabetes with unmatched efectiveness regrading glycaemic control and body weight reduction.Cardiovascular Diabetology. (2022) 21:169. 2,德邦证券;减...
1,Nauck and DAlessio; Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type2 diabetes with unmatched efectiveness regrading glycaemic control and body weight reduction.Cardiovascular Diabetology. (2022) 21:169. 2,德邦证券;减重药物专题:400 亿量级黄金赛道,GLP1 类药物减重市...
4.le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. 5. Carel W. le Roux, Oren Steen, Kathryn J. Lucas...
今年,在美国,第一种用于治疗2型糖尿病的双激动剂(dual agonist)药物已被批准上市。这种双激动剂药物结合了GLP-1和GIP(glucose-dependent insulinotropic polypeptide, 葡萄糖依赖性胰岛素多肽)受体激动剂,模拟了肠道激素GLP-1和GIP的作用。 参考资料: Carmelo Quarta et al. GLP-1-mediated delivery of tesaglitazar...
Recent updates on GLP-1 agonists: Current advancements & challenges; 信达生物 | www.innoventbio.com; 合作协议披露https://investor.innoventbio.com/media/1109/exclusive.pdf; Ji L, Jiang H, An P, et al. (2021) IBI362 (LY3305677), a weekly-doseGLP-1and glucagon receptor dual agonist, in...
参考文献:Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology. Published online July 2024. doi:10.1016/j.jhep.2024.07.006...
Provided are a GLP-1/glucagon dual agonist and the use thereof. The GLP-1/glucagon dual agonist is a GLP-1 mutant protein, which can bind and activate the activities of the class B G-protein-coupled receptor GLP-1R and the glucagon receptor. By means of administering the agonist, the ...
, PNAS)在线发表了题为“Structural analysis of the dual agonism at GLP-1R and GCGR”的研究成果(图1)。这篇由2012年诺贝尔化学奖得主Robert J. Lefkowitz教授主审的PNAS直投(Direct Submission)论文报道了胰高血糖素样肽-1受体(Glucagon-like peptide-1 receptor, GLP-1R)和...
跟GIP不一样,GLP-1一开始就备受关注,虽然GIP分泌更多,而且一直被怀疑可能比GLP-1更能刺激胰岛素分泌,但GIP有几个弊端,第一,它不知为啥,得了糖尿病这个GIP就不灵了,再多都不能刺激胰岛素分泌,也就是GIP也抵抗了;其二,它刺激胰岛素的同时,也刺激“胰高血糖素”(glucagon)的分泌,胰高血糖素跟胰岛素是对着干的...